Cite
Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels.
MLA
Sohn, Sung-Hwa, et al. “Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels.” International Journal of Molecular Sciences, vol. 21, no. 17, Sept. 2020, p. 6027. EBSCOhost, https://doi.org/10.3390/ijms21176027.
APA
Sohn, S.-H., Sul, H. J., Kim, B., Kim, B. J., Kim, H. S., & Zang, D. Y. (2020). Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels. International Journal of Molecular Sciences, 21(17), 6027. https://doi.org/10.3390/ijms21176027
Chicago
Sohn, Sung-Hwa, Hee Jung Sul, Bohyun Kim, Bum Jun Kim, Hyeong Su Kim, and Dae Young Zang. 2020. “Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels.” International Journal of Molecular Sciences 21 (17): 6027. doi:10.3390/ijms21176027.